


Stanford



Felipe Vences Catalan

Instructor, Medicine - Oncology

Bio

ACADEMIC APPOINTMENTS

- Instructor, Medicine - Oncology

PROFESSIONAL EDUCATION

- Master of Science, CINVESTAV-IPN , MOLECULAR BIOMEDICINE (2008)
- PhD, CINVESTAV-IPN , MOLECULAR BIOMEDICINE (2012)

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

My current research focuses on understanding the biology of cancer, more specifically how Tetraspanin molecules contribute to the development and spread of cancer. I am also interested in unraveling the interaction of immune cells in the tumor microenvironment and how we can use immunotherapy to treat lymphoma and breast cancer aiming towards translational medicine.

Publications

PUBLICATIONS

- **CD81 is a novel immunotherapeutic target for B cell lymphoma.** *The Journal of experimental medicine*
Vences-Catalan, F., Kuo, C., Rajapaksa, R., Duault, C., Andor, N., Czerwinski, D. K., Levy, R., Levy, S.
2019
- **EspH Suppresses Erk by Spatial Segregation from CD81 Tetraspanin Microdomains** *INFECTIO AND IMMUNITY*
Ramachandran, R., Vences-Catalan, F., Wiseman, D., Ziotkin-Rivkin, E., Shteyer, E., Melamed-Book, N., Rosenshine, I., Levy, S., Aroeti, B.
2018; 86 (10)
- **Immune Targeting of Tetraspanins Involved in Cell Invasion and Metastasis** *FRONTIERS IN IMMUNOLOGY*
Vences-Catalan, F., Levy, S.
2018; 9: 1277
- **Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression** *CANCER IMMUNOLOGY IMMUNOTHERAPY*
Hebb, J. O., Mosley, A. R., Vences-Catalan, F., Rajasekaran, N., Rosen, A., Ellmark, P., Felsher, D. W.
2018; 67 (1): 47–60
- **CD81 association with SAMHD1 enhances HIV-1 reverse transcription by increasing dNTP levels** *NATURE MICROBIOLOGY*
Rocha-Perugini, V., Suarez, H., Alvarez, S., Lopez-Martin, S., Lenzi, G. M., Vences-Catalan, F., Levy, S., Kim, B., Munoz-Fernandez, M. A., Sanchez-Madrid, F., Yanez-Mo, M.
2017; 2 (11): 1513–22

- **Tetraspanin CD81 Promotes Tumor Growth and Metastasis by Modulating the Functions of T Regulatory and Myeloid-Derived Suppressor Cells** *CANCER RESEARCH*
Vences-Catalan, F., Rajapaksa, R., Srivastava, M. K., Marabelle, A., Kuo, C., Levy, R., Levy, S.
2015; 75 (21): 4517-4526
- **A mutation in the human tetraspanin CD81 gene is expressed as a truncated protein but does not enable CD19 maturation and cell surface expression** *JOURNAL OF CLINICAL IMMUNOLOGY*
Vences-Catalan, F., Kuo, C., Sagi, Y., Chen, H., Kela-Madar, N., van Zelm, M. C., van Dongen, J. J., Levy, S.
2015; 35 (3): 254-263
- **Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein.** *PLoS one*
Al Olaby, R. R., Cocquerel, L., Zemla, A., Saas, L., Dubuisson, J., Vielmetter, J., Marcotrigiano, J., Khan, A. G., Vences Catalan, F., Perryman, A. L., Freundlich, J. S., Forli, S., Levy, et al
2014; 9 (10)
- **The CD19/CD81 complex physically interacts with CD38 but is not required to induce proliferation in mouse B lymphocytes** *IMMUNOLOGY*
Vences-Catalan, F., Rajapaksa, R., Levy, S., Santos-Argumedo, L.
2012; 137 (1): 48-55
- **Tspan33 is Expressed in Transitional and Memory B Cells, but is not Responsible for High ADAM10 Expression** *SCANDINAVIAN JOURNAL OF IMMUNOLOGY*
Perez-Martinez, C. A., Maravillas-Montero, J. L., Meza-Herrera, I., Vences-Catalan, F., Zlotnik, A., Santos-Argumedo, L.
2017; 86 (1): 23-30
- **CD81 as a tumor target.** *Biochemical Society transactions*
Vences-Catalán, F., Duault, C., Kuo, C., Rajapaksa, R., Levy, R., Levy, S.
2017; 45 (2): 531-535
- **Tetraspanin CD81, a modulator of immune suppression in cancer and metastasis** *ONCOIMMUNOLOGY*
Vences-Catalan, F., Rajapaksa, R., Srivastava, M. K., Marabelle, A., Kuo, C., Levy, R., Levy, S.
2016; 5 (5): e1120399
- **Role of an arginine-lysine rich motif in maturation and trafficking of CD19.** *Biochemical and biophysical research communications*
Vences-Catalán, F., Kuo, C., Levy, S.
2015; 465 (3): 319-323
- **TSPAN33 is a novel marker of activated and malignant B cells.** *Clinical immunology*
Luu, V. P., Hevezi, P., Vences-Catalan, F., Maravillas-Montero, J. L., White, C. A., Casali, P., Llorente, L., Jakez-Ocampo, J., Lima, G., Vilches-Cisneros, N., Flores-Gutiérrez, J. P., Santos-Argumedo, L., Zlotnik, et al
2013; 149 (3): 388-399
- **Consequences of two naturally occurring missense mutations in the structure and function of Bruton agammaglobulinemia tyrosine kinase** *IUBMB LIFE*
Vargas-Hernandez, A., Lopez-Herrera, G., Maravillas-Montero, J. L., Vences-Catalan, F., Mogica-Martinez, D., Rojo-Dominguez, A., Espinosa-Rosales, F. J., Santos-Argumedo, L.
2012; 64 (4): 346-353
- **CD38 Through the Life of a Murine B Lymphocyte** *IUBMB LIFE*
Vences-Catalan, F., Santos-Argumedo, L.
2011; 63 (10): 840-846